These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 489709)

  • 1. Inhibition of peripheral aromatization of androstenedione to estrone in postmenopausal women with breast cancer using delta 1-testololactone.
    Barone RM; Shamonki IM; Siiteri PK; Judd HL
    J Clin Endocrinol Metab; 1979 Nov; 49(5):672-6. PubMed ID: 489709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo effects of delta 1-testololactone on peripheral aromatization.
    Judd HL; Barone RM; Laufer LR; Gambone JC; Monfort SL; Lasley BL
    Cancer Res; 1982 Aug; 42(8 Suppl):3345s-3348s. PubMed ID: 7083208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Origin of serum estradiol in postmenopausal women.
    Judd HL; Shamonki IM; Frumar AM; Lagasse LD
    Obstet Gynecol; 1982 Jun; 59(6):680-6. PubMed ID: 7078905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of estrogen synthesis in human breast tumors by testololactone and bromoandrostenedione.
    Budnick RM; Dao TL
    Steroids; 1980 May; 35(5):533-41. PubMed ID: 7394858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen synthesis in human breast tumor and its inhibition by testololactone and bromoandrostenedione.
    Dao TL
    Cancer Res; 1982 Aug; 42(8 Suppl):3338s-3341s. PubMed ID: 7083197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum 17 beta-estradiol and estrone levels in postmenopausal women with and without endometrial cancer.
    Judd HL; Lucas WE; Yen SS
    J Clin Endocrinol Metab; 1976 Aug; 43(2):272-8. PubMed ID: 950362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with high-dose estrogen (diethylstilbestrol) significantly decreases plasma estrogen and androgen levels but does not influence in vivo aromatization in postmenopausal breast cancer patients.
    Geisler J; Haynes B; Anker G; Helle H; Ekse D; Dowsett M; Lønning PE
    J Steroid Biochem Mol Biol; 2005 Sep; 96(5):415-22. PubMed ID: 16168635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report.
    Goss PE; Powles TJ; Dowsett M; Hutchison G; Brodie AM; Gazet JC; Coombes RC
    Cancer Res; 1986 Sep; 46(9):4823-6. PubMed ID: 2942241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of peripheral aromatization in baboons by an enzyme-activated aromatase inhibitor (MDL 18,962).
    Longcope C; Femino A; Johnston JO
    Endocrinology; 1988 May; 122(5):2007-11. PubMed ID: 3359974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of diurnal variation in plasma levels of androstenedione, testosterone, estrone and estradiol in postmenopausal women.
    Lønning PE; Dowsett M; Jacobs S; Schem B; Hardy J; Powles TJ
    J Steroid Biochem; 1989; 34(1-6):551-3. PubMed ID: 2626050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen-estrogen production rates in postmenopausal women with breast cancer.
    Kirschner MA; Cohen FB; Ryan C
    Cancer Res; 1978 Nov; 38(11 Pt 2):4029-35. PubMed ID: 568029
    [No Abstract]   [Full Text] [Related]  

  • 12. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients.
    Dowsett M; Cunningham DC; Stein RC; Evans S; Dehennin L; Hedley A; Coombes RC
    Cancer Res; 1989 Mar; 49(5):1306-12. PubMed ID: 2917360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian steroid secretion in postmenopausal women with and without endometrial cancer.
    Nagamani M; Hannigan EV; Dillard EA; Van Dinh T
    J Clin Endocrinol Metab; 1986 Mar; 62(3):508-12. PubMed ID: 3944235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of peripheral aromatization in postmenopausal women with breast cancer.
    Barone RM; Judd HL
    Surg Forum; 1978; 29():172-4. PubMed ID: 401126
    [No Abstract]   [Full Text] [Related]  

  • 15. Steroid hormone profiles in women treated with aminoglutethimide for metastatic carcinoma of the breast.
    Samojlik E; Santen RJ; Kirschner MA; Ertel NH
    Cancer Res; 1982 Aug; 42(8 Suppl):3349s-3352s. PubMed ID: 7083199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels.
    Geisler J; Haynes B; Ekse D; Dowsett M; Lønning PE
    J Steroid Biochem Mol Biol; 2007 Apr; 104(1-2):27-34. PubMed ID: 17350249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced conversion of androstenedione to estrogens in obese males.
    Kley HK; Deselaers T; Peerenboom H; Krüskemper HL
    J Clin Endocrinol Metab; 1980 Nov; 51(5):1128-32. PubMed ID: 7419688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum concentrations of estrone, androstenedione, testosterone and sex-hormone-binding globulin in postmenopausal women with breast cancer and in age-matched controls.
    Adami HO; Johansson ED; Vegelius J; Victor A
    Ups J Med Sci; 1979; 84(3):259-74. PubMed ID: 575585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer.
    Reed MJ; Lai LC; Owen AM; Singh A; Coldham NG; Purohit A; Ghilchik MW; Shaikh NA; James VH
    Cancer Res; 1990 Jan; 50(1):193-6. PubMed ID: 2293555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of oral androstenedione administration on serum testosterone and estradiol levels in postmenopausal women.
    Leder BZ; Leblanc KM; Longcope C; Lee H; Catlin DH; Finkelstein JS
    J Clin Endocrinol Metab; 2002 Dec; 87(12):5449-54. PubMed ID: 12466335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.